Breakthrough Alzheimer's Drug Administered to First Patient at Harborview Medical Center by UW Medicine
The first patient to receive the new Alzheimer's drug, lecanemab, was treated at Harborview Medical Center in Seattle. Lecanemab, approved by the FDA, has shown to reduce cognitive decline in patients with early Alzheimer's disease. Although the benefits are modest, with a 27% slowing of cognitive decline over 18 months, it is considered a step in the right direction. The drug is approved for use by patients with amyloid plaques and mild cognitive impairment or very mild Alzheimer's dementia.